Co-Diagnostics (CODX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
4 Sep, 2026Executive summary
Annual Meeting of Stockholders originally scheduled for September 3, 2026, has been adjourned to September 24, 2026, at 9:00 a.m. Mountain Time at the company's Salt Lake City offices.
Supplementary materials were issued to inform shareholders of the new meeting date and location.
Voting matters and shareholder proposals
Shareholders are advised to review the definitive proxy statement and supplemental materials in preparation for the rescheduled Annual Meeting.
Shareholder rights and capital structure
No fee was required for the filing of the definitive additional proxy materials.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Co-Diagnostics
- Approval sought for warrant exercise, reverse stock split, and adjournment authority.CODX
Proxy filing - ReadyGo collaboration and automation drive blood-based testing, rapid outbreak response, and global expansion.CODXStatus update
- Registering 3.4M shares for resale; up to $5.31M in proceeds possible from warrant exercises.CODXRegistration filing
- Net loss narrowed as regulatory milestones advanced and global commercialization expanded.CODXQ2 2026
- Annual meeting covers director elections, equity plan, pay, auditor, quorum, and adjournment.CODXProxy filing
- Proxy covers director elections, equity plan, compensation, auditor, and governance changes.CODXProxy filing
- Resale registration for 4.94M shares enables potential $5.18M capital, but poses dilution risk.CODXRegistration filing
- Q3 revenue dropped and net loss widened as diagnostics pipeline and cash reserves remained strong.CODXQ3 2024
- Net loss narrowed to $7.5M as PCR pipeline advanced, but liquidity risks remain.CODXQ1 2025